BioBridgeX
Log inCompare quotes
Clinical

Pharmacovigilance & Drug Safety CROs

Free for buyersNeutral marketplace
Quick answer

Pharmacovigilance and drug safety is the ongoing monitoring of a drug's safety in clinical trials and after approval: collecting adverse events, processing cases, reporting to regulators, and detecting signals. You need it before first dose and through the product's life. On BioBridgeX, sponsors source and compare qualified, GCP-compliant safety CROs and contract directly with their chosen supplier, free for buyers.

Pharmacovigilance & Drug Safety CROs on BioBridgeX

We are qualifying and publishing Pharmacovigilance & Drug Safety CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is pharmacovigilance and drug safety, and when do you need it?

Pharmacovigilance (PV) is the system that watches what your drug does to patients once people start taking it, and keeps watching for the life of the product. In practical terms it is the machinery for collecting adverse events, turning each one into a properly documented case, deciding whether it has to be reported to a regulator and how fast, and standing back periodically to ask whether the accumulating data is telling you something new about the drug's safety. The discipline exists because a clinical program, however clean, only ever sees a fraction of the patients who will eventually be exposed, and rare or delayed harms surface only as numbers grow.

The timing question trips up a lot of first-time sponsors. Pharmacovigilance is not a Phase 3 problem or a post-launch problem; the safety database and the reporting infrastructure have to be live and tested before the first subject is dosed in your first-in-human study. The moment an IND or CTA is active, you own a legal obligation to capture serious adverse events and to file expedited reports (a 7-day or 15-day clock for suspected unexpected serious adverse reactions, the SUSARs) on a schedule the FDA and EMA enforce strictly. Miss the window and you have a finding waiting for you at inspection, regardless of how good the underlying science was.

The work scales with the program. In early trials it is mostly individual case safety report (ICSR) processing and SUSAR reporting against a small, controlled population. As you move into larger and post-marketing settings, the center of gravity shifts toward aggregate reporting (the DSUR during development, the PBRER and PADER after approval), structured signal detection, and a documented safety management system with a qualified person for pharmacovigilance (QPPV) if you are operating in the EU. Most biotechs do not build this in-house. They source a specialist PV CRO or a functional safety provider, which is exactly the comparison this page is built to help you run.

What does a pharmacovigilance and drug safety CRO actually do?

A PV CRO runs the parts of drug safety that are too specialized, too regulated, or too around-the-clock for a lean clinical team to staff alone. The core of the job is case management: receiving an adverse event from any source (a site, a call center, a literature alert, a partner), triaging it for seriousness and expectedness, coding the event and the drugs with MedDRA and WHODrug, writing a medically coherent narrative, having a physician assess causality, and submitting the result as an E2B(R3) ICSR to the right authorities through gateways like the FDA's FAERS and the EMA's EudraVigilance.

Beyond individual cases, a good safety provider owns the recurring deliverables and the watching brief that sit on top of them. The list below covers what sponsors typically buy, though the exact mix depends on whether you are pre-approval, post-launch, or both.

  • Case processing and ICSR management: intake, triage, MedDRA and WHODrug coding, narrative writing, medical review, and quality control across the full case lifecycle.
  • Expedited regulatory reporting: SUSAR and 7-day/15-day submissions to FDA, EMA, and other agencies via E2B(R3) electronic gateways, with reconciliation against the clinical database.
  • Aggregate safety reports: DSURs during development, plus PBRERs, PADERs, and PSURs after approval, drafted, medically reviewed, and submitted on regulatory timelines.
  • Signal detection and management: routine review of the safety database, disproportionality analysis, signal validation and assessment, and risk-benefit evaluation.
  • Safety database and system management: a validated database such as Argus or ArisGlobal LifeSphere, configured, hosted, and maintained under GxP, with a clean audit trail.
  • Risk management and EU obligations: Risk Management Plans (RMPs), REMS support, literature surveillance, a 24/7 medical-information call center, and provision of a qualified person for pharmacovigilance (QPPV) and the EU PSMF where required.

How do you choose a pharmacovigilance and drug safety CRO?

The headline rate per case is the least useful number to start with. What separates a safe partner from a costly one is whether their quality system, capacity, and inspection history actually fit the program you are running, and whether they can stand behind their data when an FDA or EMA inspector arrives. Score two or three candidates against the same written scope (case volume, geographies, modality, reporting obligations) rather than collecting quotes that quietly measure different things.

Walk down this checklist before you sign:

  • Quality and GxP status: confirm a GCP- and GVP-compliant pharmacovigilance system, validated safety database under GxP, written SOPs, and a recent FDA and EMA inspection history you can review.
  • Capacity and lead time: ask about realistic onboarding time (database setup, safety management plan, and reconciliation processes have to be live before first dose), current case backlog, and how they staff a sudden volume spike from a large trial or a safety event.
  • Modality and indication fit: a team fluent in small-molecule oncology safety may be new to gene therapy, vaccines, or cell therapy, where the adverse-event profile and the expectedness assessment differ sharply. Ask for comparable program experience.
  • Region and regulatory track record: confirm they can report into the jurisdictions you actually file in (FDA, EMA, PMDA, NMPA), provide an EU QPPV and PSMF if you operate in Europe, and show a clean record with those authorities.
  • Data quality and reconciliation: clean MedDRA coding, defensible causality narratives, and a documented process to reconcile the safety database against the clinical (EDC) database, because mismatches between the two are a classic inspection finding.
  • IP and confidentiality: clear terms on data ownership, breach notification, and how patient-level safety data is handled, especially when a partner or licensee shares the obligation.

Frequently asked questions

When do I need to set up pharmacovigilance for my trial?
Before the first subject is dosed. The moment your IND or CTA is active you have a legal duty to capture serious adverse events and file expedited SUSAR reports on a 7-day or 15-day clock, so the safety database, the safety management plan, and the reconciliation process all have to be live and tested before first-in-human dosing. Retrofitting PV after a trial starts is how sponsors end up with inspection findings, so treat it as a startup activity that runs in parallel with site activation, not something you bolt on later.
What is the difference between case processing and aggregate reporting?
Case processing handles individual adverse events one at a time: intake, triage, MedDRA and WHODrug coding, narrative writing, causality assessment, and submission of each ICSR to regulators, often against tight expedited clocks. Aggregate reporting steps back and summarizes the whole safety picture over a period: the DSUR during clinical development, and the PBRER, PADER, or PSUR after approval. One is real-time and case-by-case; the other is periodic and analytical. Most PV CROs do both, but the volume mix and the staffing shift as you move from early trials to a marketed product.
Do I need a qualified person for pharmacovigilance (QPPV)?
You need a QPPV if you hold a marketing authorization in the EU, and many sponsors also appoint one earlier when running EU clinical trials. The QPPV is a named individual, resident in the EU or UK, personally accountable for the pharmacovigilance system and reachable around the clock by the authorities. You also maintain a Pharmacovigilance System Master File (PSMF). Many PV CROs provide a contracted QPPV and PSMF management as a service, which is a common reason smaller sponsors outsource European safety rather than build it in-house. If you only operate under a US IND, the QPPV requirement does not apply, though you still owe FDA expedited and periodic reporting.
How much does outsourcing pharmacovigilance cost?
It depends on case volume, geographies, and which deliverables you need, so a single figure would mislead you. The reliable cost drivers are the number of ICSRs processed (usually priced per case, with serious and complex cases costing more), whether you are paying for a hosted and validated safety database, how many aggregate reports and signal-detection cycles fall in the period, and whether a 24/7 call center or a contracted QPPV is included. Early-phase programs with low case volume are relatively cheap; a marketed product with global reporting obligations is not. Get a per-case rate and a clear list of what aggregate reports and system costs are bundled versus billed separately, then compare suppliers against the same case-volume assumption.
What is MedDRA coding and why does it matter for safety data?
MedDRA (the Medical Dictionary for Regulatory Activities) is the standardized terminology regulators require for classifying adverse events. Coding an event to the right MedDRA term is what lets the FDA, EMA, and others aggregate cases across trials and across companies and spot patterns. Inconsistent or sloppy coding is more than a tidiness problem: it can hide a real safety signal or manufacture a false one, and it is a recurring inspection finding. When you evaluate a PV CRO, the discipline and quality control around their MedDRA and WHODrug coding is a direct proxy for how trustworthy their safety database will be.
Can one CRO handle both my clinical operations and pharmacovigilance?
Yes, many full-service CROs bundle pharmacovigilance with clinical operations under one master agreement, and that single point of accountability appeals to lean teams. The alternative, common among larger or more experienced sponsors, is to contract a specialist safety provider separately on a functional basis, which keeps PV independent and lets you pick the best safety team rather than accepting whoever your clin-ops CRO happens to staff. There is no universally right answer. What matters is that whoever owns PV runs a validated system, reconciles cleanly against the clinical database, and has the inspection track record to back it up. On BioBridgeX you can source a bundled or a standalone safety supplier and still contract once across the program.

Source Pharmacovigilance & Drug Safety with one contract

Compare transparent quotes from qualified Pharmacovigilance & Drug Safety CROs, then contract once. Free for buyers.

Compare quotes